Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash & Equivalents (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Cash & Equivalents for 8 consecutive years, with $69.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 28.52% year-over-year to $69.6 million, compared with a TTM value of $69.6 million through Sep 2025, down 28.52%, and an annual FY2024 reading of $55.7 million, down 43.86% over the prior year.
  • Cash & Equivalents was $69.6 million for Q3 2025 at X4 Pharmaceuticals, up from $39.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $147.2 million in Q2 2024 and bottomed at $39.2 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $87.1 million, with a median of $81.8 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents surged 187.96% in 2023, then plummeted 73.36% in 2025.
  • Year by year, Cash & Equivalents stood at $81.8 million in 2021, then surged by 48.82% to $121.7 million in 2022, then decreased by 18.49% to $99.2 million in 2023, then tumbled by 43.86% to $55.7 million in 2024, then increased by 25.01% to $69.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for XFOR at $69.6 million in Q3 2025, $39.2 million in Q2 2025, and $40.3 million in Q1 2025.